Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, with an emphasis on oncology and autoimmune diseases, and additional programs in infectious and neurological disorders. Based in China with operations in the United States, the company combines internal R&D with strategic partnerships to advance novel therapies and expand access to leading global treatments in Greater China.
Founded in 2014, Zai Lab has built capabilities across clinical development, regulatory affairs, and commercialization, supporting multiple approved products in China and a diversified clinical pipeline. The company participates in global trials and collaborations to accelerate development timelines and align with international standards. Zai Lab is listed on Nasdaq (ticker: ZLAB) and the Hong Kong Stock Exchange (stock code: 9688).
None yet. When a new project in the record names Zai Lab as owner, partner or investor, it shows here.
Primary endpoint met in Phase 3 ALKIVIA: efgartigimod improved mean Total Improvement Score at Week 52 versus placebo; benefit emerged by Week 4 and was sustained across IMNM and DM.
Phase Ib/II testing obrixtamig (DLL3/CD3 T‑cell engager) plus zoci (zocilurtatug pelitecan, DLL3 ADC) in ES‑SCLC and other NECs to assess safety, tolerability and early clinical activity
